Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
Should we use the word 'cure' in CLL?
The main challenges facing practitioners treating APL
Comparison of native vs pegylated asparaginase for HR Ph chromosome-negative ALL
Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLL